Vanda CEO reveals NEREUS launch plan: DTC channel, availability in months

Vanda Pharmaceuticals Inc.

NEREUS approved by FDA for prevention of vomiting induced by motion sickness.
CEO disclosed development of direct-to-consumer channel NEREUSRX for NEREUS access.
NEREUS will be available in the next couple of months per CEO on Fox Business.
Pricing and commercial strategy for NEREUS discussed during interview.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.